Other News To Note
Wednesday, July 17, 2013
Advancell SA, of Barcelona, Spain, and Helsinn Healthcare SA, of Lugano, Switzerland, signed a partnering agreement to develop and commercialize ATH008, a topical product designed to prevent and treat palmoplantar erythrodysesthesia syndrome, or PPES, often caused by fluoropyrimidines-based chemotherapy, and hand-foot skin reactions, or HFSR, often caused by multitargeted kinase inhibitors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.